Roth Capital Initiates Buy On Hyperion Therapeutics, Sees 38% Upside
Roth Capital analyst Debjit Chattopadhyay initiated coverage on Hyperion Therapeutics (NASDAQ:HPTX) with a Buy rating and a $34 price target, which represents a potential upside of 38% from where the stock is currently trading.
Chattopadhyay wrote, “Hyperion is well positioned to expand its GI-focused rare/orphan disease franchise by leveraging key insights in the role of ammonia control in Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE). We estimate 20% YoY revenue growth from the UCD franchise and believe that HE is an under-the-radar pipeline opportunity. Based on our conviction that Glycerol PhenylButyrate (GPB) could become the standard-of-care in both UCD and HE we initiate with a Buy rating.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -11.7% and a 36.7% success rate. Chattopadhyay is ranked #3301 out of 3358 analysts.